A recent Health Technology Assessment (HTA) report by the United Kingdom’s National Institute for Health and Care Excellence (NICE) concludes that adalimumab, etanercept, and ustekinumab improve the symptoms of psoriasis in children and young people in the short term, but the cost-effectiveness of these medications requires further study.
A recent Health Technology Assessment (HTA) report by the United Kingdom’s National Institute for Health and Care Excellence (NICE) concludes that adalimumab, etanercept, and ustekinumab all improve the symptoms of psoriasis in children and young people in the short term, but because there is such a limited body of evidence on the use of these drugs in children, the effects of biologic therapies later in patients’ lives are unclear, and the cost-effectiveness of these medications requires further study.
NICE researchers, led by Ana Duarte, MD, investigated health-related quality of life (QOL) gains associated with treatment, as well as the number of hospitalizations in children and young people with plaque psoriasis who were using 1 of the 3 biologics approved for use by the United Kingdom’s National Health Service (NHS) for that indication. They found that biological treatments appear to offer some benefits, but may not be cost-effective for the management of psoriasis in children and young people at the willingness-to-pay threshold of £30,000 (approximately $39,735) per quality-adjusted life-year unless an assumption is made that the consequences of biologic treatment long-term in children are the same as those in adults.
The cost-effectiveness analysis considered 3 separate populations:
The report concluded the following:
Finally, the authors advise continued collection of data through registries of biological therapies for individuals aged under 18 years. These data will allow researchers to better understand safety, patterns of treatment switching, impact on comorbidities, and long-term withdrawal rates for these therapies. The uncertainty surrounding the effectiveness of biological treatments in children and young people could be substantially reduced through adequately powered randomized clinical trials, which are currently lacking.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.